Abdominal Aortic Aneurysm (AAA)
Conditions
Keywords
Abdominal Aortic Aneurysm, AAA, Aneurysm
Brief summary
The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).
Detailed description
This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. Upon completion of enrollment of150 subjects, an additional 50 subjects may be treated with the Treovance Stent-Graft at the 30 investigative sites participating in the trial. These additional subjects will follow the same study schedule, and data from these patients may be used to supplement the pivotal trial data. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted. Subjects with fracture(s) confirmed by the Core Lab within the first 5 years will be followed for an additional 5 years, for a total of 10 years post-implantation. The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S. There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms: * Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant * Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days Secondary objectives involve assessment of major device-related events and major morbidity.
Interventions
DEVICESubjects who receive the Treovance stent-graft
Eligible subjects will be implanted with the Treovance Stent-Graft
Sponsors
Bolton Medical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
AAA Device
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Subject must be between the ages of 18 and 85 2. Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement, by CT with contrast performed within 4 months of planned implant procedure 3. Subject must have an infrarenal AAA that i. is \> 4.5 cm in diameter for males, or \> 4.0 cm in diameter for females, or ii. has increased in diameter by 0.5 cm in the last 6 months 4. Subject must have i. infrarenal landing neck length of 10 mm or greater and an angle of less than 60 degrees relative to the long axis of the aneurysm (centerline at lowest renal to centerline at bifurcation) and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 17 mm -32 mm, or ii. infrarenal landing neck length of 15 mm or greater and an angle of between 60 and 75 degrees relative to the long axis of the aneurysm and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 16 mm-30 mm 5. Subject's infrarenal landing neck must meet the vessel size requirements specified in the instructions for use (IFU) for the corresponding devices 6. Subject must have lowest renal artery at least 9 cm from the aortic bifurcation 7. Subject must have a distal iliac landing neck with i. an inside diameter of 8 mm - 13 mm and a length of at least 10 mm, or ii. an inside diameter of \>13 mm - 20 mm and a length of at least 15 mm 8. Subject's distal iliac landing neck must meet the vessel size requirements specified for the corresponding devices in the IFU 9. Subject must have a total treatment length of at least 13 cm 10. Subject must have a distal aortic diameter above the iliac bifurcation equal to or greater than 70% of the sum of the selected leg graft diameters that will pass through the same 11. Subject must be willing and able to comply with 1-month, 6-month, and 12-month follow-up visits, as well as annual visits out to 5 years 12. Subject must have adequate renal function to tolerate required follow-up contrast-enhanced CTs 13. Subject must have adequate vascular access (e.g., patent iliac or femoral arteries) for introduction of the Navitel Delivery System, which is 18F (6 mm) or 19F (6.3 mm) outer diameter based on size of device used. Alternatively, subject's anatomy is suitable for creation of an iliac conduit. 14. Subject or Legally Authorized Representative (LAR) must agree to sign Informed Consent Form
Exclusion criteria
1. Subject is pregnant or lactating 2. Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician) 3. Subject has a patent inferior mesenteric artery that cannot be sacrificed and an occluded or stenotic celiac and/or superior mesenteric artery 4. Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging 5. Subject has a lesion that cannot be crossed by a guide wire 6. Proximal neck cannot increase by more than 10% over 15mm or more than 7% over 10mm; i.e., no trapezoidal necks 7. Subject has severe untreated coronary artery disease and/or unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction \< 20%, or recent diagnosis of Congestive Heart Failure (CHF) 8. Subject has had a stroke or myocardial infarction within 6 months of the planned treatment date 9. Subject has chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use) 10. Subject has an active systemic infection or is suspected of having an active systemic infection (e.g.,AIDS/HIV, sepsis) 11. Subject is morbidly obese (more than 100% over the ideal body weight or as defined by institutional standards) or has other clinical conditions that severely compromise or impair x-ray visualization of the aorta 12. Subject has connective tissue disease (e.g., Marfan's syndrome) 13. Subject has a mycotic aneurysm 14. Subject has significant or circumferential calcification or mural thrombus in the proximal aortic neck 15. Subject has significant or circumferential calcification or mural thrombus in the distal iliac landing zone 16. Subject has significant or circumferential calcification or mural thrombus within the treatment length, which may adversely impact device patency 17. Subject has a blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair 18. Subject is in acute or chronic renal failure (creatinine \> 2.5 mg/dL) unless subject is stable on dialysis 19. Subject has less than two-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignancy, severe cardiopulmonary disease, etc.) 20. Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure 21. Subject is confronted with other medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up. These reasons must be documented. An example may include adherence to a theological or personal doctrine with aversion or opposition to blood transfusion. 22. Subject has had a prior AAA repair (endovascular or surgical) 23. Subject has an untreatable allergy or sensitivity to contrast media, nitinol/nickel, or polyester 24. Subject has undergone other major surgical or medical intervention within 45 days of the planned procedure or is planning to undergo other major surgical or medical intervention within 45 days post implantation (e.g., Coronary Artery Bypass Graft (CABG), organ transplantation, renal stenting, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Safety | 30 days | The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.) |
| Primary Efficacy | 12 months | Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Efficacy Endpoint -- Secondary interventions | 30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only) | The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant |
| Secondary Efficacy Endpoint -- Device-Related Events | 30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only) | This endpoint includes the rate of events associated with the device. |
| Secondary Efficancy Endpoint -- Aneurysm-Related Mortality | Annually to 5-years; annually to 10-years (stent-fracture subjects only) | Aneurysm-related mortality at 12 month and annually to 5 years; annually to 10 years for subjects with Core Lab-confirmed fracture(s) |
| Secondary Safety Endpoint -- Individual Rate for Events included in the composite MAE | 30 days, 6 months, annually to 5 years | Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually to 5 years |
| Secondary Efficacy Endpoint -- Technical Success | 30 days | Technical success at 30 days confirmed by an imaging modality (e.g. CT) |
| Secondary Safety Endpoint -- Procedure-Related Complications | 30 days, 6 months, annually to 5 years | Procedure-related complications at 30 days, 6 months, 12 months, and annually to 5 years. |
| Secondary Efficacy Endpoint -- Clinical Utility Measures | Perioperative/Periprocedural | Clinical utility measures (procedure time, time in the intensive care unit, length of hospital stay) |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMatthew Eagleton, MD
Cleveland Clinic Foundaton
Outcome results
None listed